Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia Clinical Trials in Chicago, Illinois
2 recruitingChicago, Illinois
Showing 1–2 of 2 trials
Recruiting
Phase 1
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled21 locationsNCT06484062
Recruiting
Phase 1
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI)42 enrolled5 locationsNCT03816319